[ad_1]
People who use drugs containing valsartan as an active ingredient should NOT stop the medication without first consulting their doctor.
The National Food and Drug Monitoring Institute (INVIMA) reported, through a health alert, that international reference bodies had identified a "probably carcinogenic" substance called Nnitrosodimethylamine (NDMA) in valsartan, used to treat patients with hypertension.
For this reason, Invima and the laboratories: American Generics SAS, Genfar SA, Humax Pharmaceutical SA, Laboratoire Franco Colombiano Lafrancol SAS, MK Laboratories SAS, Lafrancol Internacional SAS, Procaps SA, Sanofi-Aventis of Colombia SA, Tecnoquímicas SA Winthrop Pharmaceuticals de Colombia SA has determined as a preventive measure the voluntary withdrawal from the market of its medicines containing Valsartan.
In addition to being in this medication, NDMA substance is present in tobacco smoke, in some processed foods and in some items.
According to the INVIMA, "the verification of the raw material supplier of other products available in the country is currently underway and the community will be informed in a timely manner."
For now, Invima pointed out that people who consume drugs containing valsartan as an active ingredient should NOT stop the drug without first consulting their doctor. "The abrupt suspension of your treatment can have serious consequences on your health."
In addition, if patients have experienced an adverse event badociated with valsartan treatment, they should report it on the Invima website. in Citizen Information Services. "-" Complaints, Claims and Complaints "-" Complaints and Complaints "-" File Procedures "-" Complaints and Complaints ".
Source link
